(LXRX) Lexicon Pharmaceuticals - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 848m USD | Total Return: 169.2% in 12m
Avg Turnover: 3.78M
Qual. Beats: 6
Rev. Trend: 96.4%
Qual. Beats: 1
Warnings
High Debt while negative Cash Flow
Interest Coverage Ratio -3.0 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader
Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical company headquartered in Texas, specializing in the development and commercialization of small molecule therapies. The company’s primary focus is on cardiometabolic disorders and neuropathic pain, with its lead compound, sotagliflozin, marketed under the brand INPEFA for heart failure management. Its pipeline includes candidates targeting obesity (LX9851) and neuropathic pain (LX9211), supported by strategic partnerships with industry leaders such as Bristol-Myers Squibb and Viatris Inc.
The biotechnology sector typically operates on a high-risk, high-reward model where success is heavily contingent on FDA approval cycles and patent protection durations. Unlike diversified pharmaceutical firms, clinical-stage and early-commercial companies like Lexicon often focus on niche molecular targets to address unmet needs in chronic disease management. You can explore further financial metrics and pipeline developments for LXRX on ValueRay.
- INPEFA commercial adoption rates drive near-term revenue growth and market share
- FDA decision on Zynquista for type 1 diabetes remains major catalyst
- Clinical trial results for LX9211 determine expansion into neuropathic pain markets
- Ongoing cash burn necessitates potential future capital raises or strategic partnerships
- Pipeline diversification into obesity treatments impacts long-term valuation and investor sentiment
| Net Income: -26.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 50.78 > 1.0 |
| NWC/Revenue: 252.9% < 20% (prev 432.9%; Δ -180.0% < -1%) |
| CFO/TA -0.14 > 3% & CFO -38.8m > Net Income -26.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (400.2m) vs 12m ago 10.54% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 24.59% > 50% (prev 10.49%; Δ 14.10% > 0%) |
| Interest Coverage Ratio: -2.99 > 6 (EBIT TTM -24.2m / Interest Expense TTM 8.09m) |
| A: 0.66 (Total Current Assets 186.0m - Total Current Liabilities 9.90m) / Total Assets 268.8m |
| B: -7.51 (Retained Earnings -2.02b / Total Assets 268.8m) |
| C: -0.09 (EBIT TTM -24.2m / Avg Total Assets 283.2m) |
| D: 3.08 (Book Value of Equity 202.9m / Total Liabilities 66.0m) |
| Altman-Z'' = -17.53 = D |
| DSRI: 0.11 (Receivables 11.8m/47.4m, Revenue 69.6m/31.2m) |
| GMI: 0.16 (GM 16.06% / 99.07%) |
| AQI: 1.82 (AQ_t 0.27 / AQ_t-1 0.15) |
| SGI: 2.23 (Revenue 69.6m / 31.2m) |
| TATA: 0.05 (NI -26.1m - CFO -38.8m) / TA 268.8m) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of June 12, 2026, the stock is trading at USD 1.89 with a total of 2,036,732 shares traded.
Over the past week, the price has changed by -0.53%,
over one month by -18.18%,
over three months by +9.88% and
over the past year by +169.19%.
Lexicon Pharmaceuticals has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold LXRX.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 3.7 | 96.8% |
P/S = 12.1823
P/B = 4.1824
P/EG = -0.14
Revenue TTM = 69.6m USD
EBIT TTM = -24.2m USD
EBITDA TTM = -23.7m USD
Long Term Debt = 49.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.64m USD (from shortTermDebt, last quarter)
Debt = 65.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.02m
Net Debt = -104.9m USD (calculated: Debt 65.7m - CCE 170.7m)
Enterprise Value = 743.5m USD (848.4m + Debt 65.7m - CCE 170.7m)
Interest Coverage Ratio = -2.99 (Ebit TTM -24.2m / Interest Expense TTM 8.09m)
EV/FCF = -57.27x (Enterprise Value 743.5m / FCF TTM -13.0m)
FCF Yield = -1.75% (FCF TTM -13.0m / Enterprise Value 743.5m)
FCF Margin = -18.64% (FCF TTM -13.0m / Revenue TTM 69.6m)
Net Margin = -37.46% (Net Income TTM -26.1m / Revenue TTM 69.6m)
Gross Margin = unknown ((Revenue TTM 69.6m - Cost of Revenue TTM 646k) / Revenue TTM)
Tobins Q-Ratio = 2.77 (Enterprise Value 743.5m / Total Assets 268.8m)
Interest Expense / Debt = 12.31% (Interest Expense 8.09m / Debt 65.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -19.1m (EBIT -24.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.43 (Total Current Assets 186.0m / Total Current Liabilities 12.9m)
Debt / Equity = 0.32 (Debt 65.7m / totalStockholderEquity, last quarter 202.9m)
Debt / EBITDA = 4.43 (negative EBITDA) (Net Debt -104.9m / EBITDA -23.7m)
Debt / FCF = 8.08 (negative FCF - burning cash) (Net Debt -104.9m / FCF TTM -13.0m)
Total Stockholder Equity = 140.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.21% (Net Income -26.1m / Total Assets 268.8m)
RoE = -18.64% (Net Income TTM -26.1m / Total Stockholder Equity 140.0m)
RoCE = -12.77% (EBIT -24.2m / Capital Employed (Equity 140.0m + L.T.Debt 49.7m))
RoIC = -7.44% (negative operating profit) (NOPAT -19.1m / Invested Capital 257.1m)
WACC = 10.66% (E(848.4m)/V(914.1m) * Re(10.73%) + D(65.7m)/V(914.1m) * Rd(12.31%) * (1-Tc(0.21)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 24.39%
[DCF] Fair Price = unknown (Cash Flow -13.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.26 | # QB: 6
Revenue Correlation: 96.39 | Revenue CAGR: 718.4% | SUE: 1.12 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.05 | Chg30d=+8.73% | Revisions=N/A | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=-19.20% | Revisions=N/A | Analysts=5
EPS current Year (2026-12-31): EPS=-0.16 | Chg30d=+12.37% | Revisions=+33% | GrowthEPS=-13.3% | GrowthRev=-23.4%
EPS next Year (2027-12-31): EPS=-0.21 | Chg30d=+0.86% | Revisions=-20% | GrowthEPS=-30.0% | GrowthRev=-47.2%
[Analyst] Revisions Ratio: +33%